EP News: Basic and Translational

The current phase 3 multi-center, randomized, double-blind, placebo-controlled trial (Olivotto et al, Lancet 2020, 10.1016/S0140-6736(20)31792-X; PMID: 32871100) was conducted to evaluate the efficacy and safety of mavacamten, a first-in-class cardiac myosin inhibitor, in symptomatic obstructive hypertrophic cardiomyopathy. Cardiac muscle hypercontractility is a key pathophysiological abnormality in hypertrophic cardiomyopathy. A total of 251 patients with hypertrophic cardiomyopathy with a left ventricular outflow tract (LVOT) gradient of 50 mm Hg or greater and New York Heart Association (NYHA) class II-III symptoms were enrolled from 68 clinical cardiovascular centers in 13 countries.
Source: Heart Rhythm - Category: Cardiology Authors: Source Type: research